Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03240393
Recruitment Status : Withdrawn (Company Decision)
First Posted : August 7, 2017
Last Update Posted : July 26, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.

Condition or disease Intervention/treatment Phase
Carcinoma Non-Small-Cell Lung Cancer Drug: INC280 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Multicenter 3-cohort Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received 1 or 2 Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Estimated Study Start Date : July 31, 2018
Estimated Primary Completion Date : October 26, 2021
Estimated Study Completion Date : October 26, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: cMET GCN ≥ 6
Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
Drug: INC280
cMET GCN ≥ 6 cMET GCN ≥ 4 and < 6 cMET mutations
Other Name: capmatinib

Experimental: cMET GCN ≥ 4 and < 6
Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
Drug: INC280
cMET GCN ≥ 6 cMET GCN ≥ 4 and < 6 cMET mutations
Other Name: capmatinib

Experimental: cMET mutations
Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
Drug: INC280
cMET GCN ≥ 6 cMET GCN ≥ 4 and < 6 cMET mutations
Other Name: capmatinib




Primary Outcome Measures :
  1. ORR based on Central Radiology review/assessment (BIRC) [ Time Frame: at least 18 weeks ]
    Proportion of patients with a best overall response defined as complete response (CR) or partial response (PR) by Blinded Independent Review Committee (BIRC) assessment per RECIST 1.1


Secondary Outcome Measures :
  1. Duration of Response (DOR) by BIRC - Key Secondary [ Time Frame: at least 18 weeks ]
    Calculated as the time from the date of the first documented CR or PR by Blinded Independent Review Committee (BIRC) per RECIST 1.1 to the first documented progression or death due to any cause for patients with PR or CR.

  2. ORR by Investigator [ Time Frame: at least 18 weeks ]
    ORR (complete response (CR)+ partial response (PR)) per RECIST 1.1 by investigator assessment

  3. Duration of Response (DOR) by investigator [ Time Frame: at least 18 weeks ]
    DOR per RECIST 1.1 by investigator assessment

  4. Time to Response (TTR) by BIRC [ Time Frame: at least 18 weeks ]
    TTR per RECIST 1.1 by BIRC assessment

  5. Time to Response (TTR) by investigator [ Time Frame: at least 18 weeks ]
    TTR per RECIST 1.1 by investigator assessment

  6. Disease Control Rate (DCR) by BIRC [ Time Frame: at least 18 weeks ]
    DCR per RECIST 1.1 by BIRC assessment

  7. Disease Control Rate (DCR) by investigator [ Time Frame: at least 18 weeks ]
    DCR per RECIST 1.1 by investigator assessment

  8. Progression-free Survival (PFS) by BIRC [ Time Frame: at least 18 weeks ]
    PFS per RECIST 1.1 by BIRC assessment

  9. Progression-free Survival (PFS) by investigator [ Time Frame: at least 18 weeks ]
    PFS per RECIST 1.1 by investigator assessment

  10. Overall Survival (OS) [ Time Frame: at least 18 weeks ]
    OS, defined as time from first dose of INC280 to death due to any cause

  11. Cmax profile of INC280 [ Time Frame: 6 weeks ]
    Pharmacokinetics of INC280

  12. Cmax profile of INC280 metabolite CMN288 [ Time Frame: 6 weeks ]
    Pharmacokinetics of INC280 metabolite CMN288

  13. Cmin profile of INC280 [ Time Frame: 6 weeks ]
    Pharmacokinetics of INC280

  14. Cmin profile of INC280 metabolite CMN288 [ Time Frame: 6 weeks ]
    Pharmacokinetics of INC280 metabolite CMN288

  15. Plasma concentration-time profiles of INC280 [ Time Frame: 6 weeks ]
    Pharmacokinetics of INC280

  16. Plasma concentration-time profiles of INC280 metabolite CMN288 [ Time Frame: 6 weeks ]
    Pharmacokinetics of INC280 metabolite CMN288



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage IIIB or IV NSCLC (any histology) at the time of study entry
  • Histologically or cytologically confirmed diagnosis of NSCLC that is:

    1. EGFR wt as per patient standard of care by a validated test
    2. AND ALK-negative rearrangement as part of the patient standard of care by a validated test
    3. AND (by central assessment) either:

      • Cohort 1: Pre-treated patients with cMET GCN ≥ 6 or
      • Cohort 2: Pre-treated patients with cMET GCN ≥4 and < 6, or
      • Cohort 3: Pre-treated patients with cMET mutations regardless of cMET GCN, or
  • Patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease
  • At least one measurable lesion as defined by RECIST 1.1
  • Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.
  • Patients must have adequate organ function
  • ECOG performance status (PS) of 0 or 1

Details and other protocol-defined inclusion criteria may apply

Exclusion Criteria:

  • Prior treatment with crizotinib, or any other cMET or HGF inhibitor
  • Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations
  • Patients with characterized ALK-positive rearrangement
  • Clinically significant, uncontrolled heart diseases.
  • Patients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study:

    • Strong and moderate inhibitors of CYP3A4
    • Strong inducers of CYP3A4
  • Impairment of GI function or GI disease that may significantly alter the absorption of INC280
  • Patients receiving treatment with any enzyme-inducing anticonvulsant
  • Previous anti-cancer and investigational agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before first dose
  • Pregnant or nursing women
  • Women of child-bearing potential, unless they are using highly effective methods of contraception
  • Sexually active males unless they use a condom during intercourse

Other protocol-defined exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03240393


Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03240393    
Other Study ID Numbers: CINC280A2202
First Posted: August 7, 2017    Key Record Dates
Last Update Posted: July 26, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Planned Shared Data Description: Copy and paste this Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Non Small Cell Lung Cancer
NSCLC
INC280
EGFR wild-type (wt)
advanced non-small cell lung cancer
advanced/metastatic disease
Non-small cell lung carcinoma (NSCLC)
treatment of lung cancer after first metastasis
lung cancer
lung adenocarcinoma
Non small cell lung carcinoma
Non-small cell lung cancer
MET exon 14 deletion
MET exon 14 skipping
MET exon 14 mutation
MET mutation
MET amplification
MET inhibitor
MET dysregulation
MET activation
MET signaling
MET pathway
MET
cMET
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms